Efficacy and Safety of TAF in Pregnant Women With Chronic Hepatitis B Infection

Summary

The effectiveness of mother-to-child block of CHB in pregnant women in the middle and later stages of pregnancy has been recognized by the guidelines. TAF, as a newly marketed antiviral drug, has not been conclusively concluded in terms of its efficacy and postpartum safety in preventing mother-to-child transmission in pregnant women.Our purpose is to explore the TAF for CHB the curative effect of pregnant and postnatal security.

Timeline

Start

2020-08-01

Primary completion

2020-12-30

Completion

2021-06-30

Drugs

Indications